Papillary Dermal Elastolysis Secondary to Combination Nivolumab and Cabiralizumab Therapy: Histiocytes and Dermal Mucin as Clues to the Diagnosis.
Papillary Dermal Elastolysis Secondary to Combination Nivolumab and Cabiralizumab Therapy: Histiocytes and Dermal Mucin as Clues to the Diagnosis.
复制标题
DOI：
10.1097/dad.0000000000001915
复制
发表时间：
2021-10-01
影响因子：
1.1
通讯作者：
Brinster, Nooshin K.
中科院分区：
文献类型：
--
作者：
Yin, Lu;Criscito, Maressa C.;Stokar, Evan;Siolas, Despina;Haimovic, Adele;Lo Sicco, Kristen;Brinster, Nooshin K.
已在实验性纳武单抗和卡比拉珠单抗联合免疫疗法的背景下描述了乳头状真皮弹力溶解。我们报告了第三例患有独特的全身萎缩性斑疹的患者，该斑疹是在治疗转移性胰腺腺癌的临床试验期间麻疹状皮疹后出现的。组织病理学结果表明，真皮乳头层弹性纤维减少，与富含组织细胞的浸润和真皮粘蛋白增加有关，这些特征应该为皮肤病理学家提供这种情况的线索。
Papillary dermal elastolysis has been described in the setting of experimental combination nivolumab and cabiralizumab immunotherapy. We report a third patient with distinctive, generalized atrophic macules that developed after a morbilliform eruption during a clinical trial for treatment of metastatic pancreatic adenocarcinoma. Histopathological findings demonstrated diminished elastic fibers in the papillary dermis, associated with a histiocyte-rich infiltrate and increased dermal mucin, features that should clue the dermatopathologist to this condition.